Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Iclusig (ponatinib; Takeda/Incyte/Otsuka)Drug Analysis Report 2018: A BCR-ABL Tyrosine Kinase Inhibitor (TKI) -

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Iclusig" drug pipelines has been added to's offering.

Iclusig (ponatinib; Takeda/Incyte/Otsuka) is a BCR-ABL tyrosine kinase inhibitor (TKI). Preclinical studies have also shown selective inhibition of other tyrosine kinases, including FLT3, RET, KIT, and the members of the fibroblast growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor families of kinases. Iclusig demonstrated inhibition of wild-type and mutated forms of BCR-ABL, including T315I, the highly drug-resistant missense mutation of BCR-ABL. In mice, treatment with Iclusig reduced the size of tumors expressing native or T315I-mutant BCR-ABL when compared to controls.

After a brief suspension due to an increased risk of arterial thrombosis, Ariad reinstated Iclusig's commercialization for patients with refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia in January 2014. This event was contingent upon US Food and Drug Administration (FDA) requirements that safety measures, additional product labeling, a Risk Evaluation and Mitigation Strategy, and post-marketing investigations be put in place prior to marketing and commercialization.

Key Topics Covered:

List of Figures

Figure 1: Iclusig for CML - SWOT analysis

Figure 2: Drug assessment summary of Iclusig for CML

Figure 3: Drug assessment summary of Iclusig for CML

Figure 4: Iclusig - SWOT analysis in acute lymphoblastic leukemia

Figure 5: Drug assessment summary for Iclusig in acute lymphoblastic leukemia

Figure 6: Drug assessment summary for Iclusig in acute lymphoblastic leukemia

List of Tables

Table 1: Iclusig drug profile

Table 2: Iclusig pivotal trial data in CML

Table 3: Iclusig late-phase trial data in CML

Table 4: Iclusig ongoing late-phase clinical trials in CML

Table 5: Iclusig drug profile

Table 6: Pivotal clinical trial data for Iclusig in acute lymphoblastic leukemia

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.